glp 1 agonist mounjaro GLP-1 receptor agonists What You Need to Know
Description
Harvard geneticist David Sinclair reveals a rare but serious blindness risk linked to GLP-1 drugs, estimating 20,00030,000 NAION cases per year in
A new blockbuster class of therapeutics, glucagon-like peptide 1 (GLP-1) analogs (eg, semaglutide), shows promise at curbing both diseases
A major new study reveals that women who discontinued these medications gained over 3 kg more during pregnancy compared to those who never used them
FDA updates rules on compounded GLP-1 drugs, impacting patients and providers
